Prophylactic treatment with tenofovir disoproxil fumarate reduced the incidence of HIV infection among injection drug users, according to data published in The Lancet.
“This study completes the picture of pre-exposure prophylaxis (PrEP) efficacy for all major HIV risk groups,” Michael Martin, MD, chief of HIV clinical research for the Thailand Ministry of Public Health – US CDC Collaboration, said in a press release. “We now know that PrEP can be a potentially vital option for HIV prevention in people at very high risk for infection, whether through sexual transmission or injection drug use.”
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.